Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Allergic Conjunctivitis: later-stage trial registry
3 of 21 indexed Allergic Conjunctivitis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 3 currently recruiting · #797 of 28,707 conditions by registered trial count
Allergic Conjunctivitis: 21 US clinical trials tracked, 3 recruiting.
Allergic Conjunctivitis is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is ORA, running 4 of these trials.
Enrollment posture brief
Registry condition allergic-conjunctivitis
OPEN 3 | RECR 14% | LATE 12 | EARLY 7 | RANK #797 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)
Allergic Conjunctivitis lists 3 open slots (14% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Allergic Conjunctivitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Allergic Conjunctivitis is recruiting below its size-band peers.
3 of 21 indexed trials (14.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Allergic Conjunctivitis research.
ORA accounts for 4 of 21 trials (19%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Allergic Conjunctivitis enrolment sits around 101 participants.
Median target enrolment is 101 among the 21 trials that report a genuine target (sentinel values excluded). 10 of those (47.6%) plan for fewer than 100 participants.
-
Allergic Conjunctivitis research is mostly interventional.
20 interventional and 1 observational studies make up this index (95.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
Regeneron Pharmaceuticals
NCT07309432
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Telios Pharma
NCT06686472
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
Telios Pharma
NCT07220408
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
Bausch & Lomb Incorporated
NCT05815758
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
Aldeyra Therapeutics
NCT03494504
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
Alcon Research
NCT01119287
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
Fovea Pharmaceuticals
NCT00833495
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
Bausch & Lomb Incorporated
NCT00770133
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
Sun Pharma Advanced Research Company Limited
NCT01320553
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
ORA
NCT03320434
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
Vistakon Pharmaceuticals
NCT00244543
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Aciex Therapeutics
NCT01881113
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
Bausch & Lomb Incorporated
NCT01107405
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
Realm Therapeutics
NCT03368339
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
Akorn
NCT01561521
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
Andover Research Eye Institute
NCT05265910
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
ORA
NCT00689078
A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season
ORA
NCT00982163
Effect of Olopatadine on Allergic Tear Mediators
University of Wisconsin, Madison
NCT00609128
Assessment of Alcon's Ocular Image Quantification System
Alcon Research
NCT01282138
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
ORA
NCT01534195
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 7 |
| Phase 3 | 7 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Allergic Conjunctivitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Allergic Conjunctivitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Allergic Conjunctivitis page
21 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Allergic Conjunctivitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- ORA sponsors the most Allergic Conjunctivitis trials on record, review their full trial history before evaluating a specific study. See ORA's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Allergic Conjunctivitis condition card totals 21 registered trials; most-linked intervention Placebo; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.